Ekso Bionics (NASDAQ:EKSO) PT Raised to $10.00 at HC Wainwright

Ekso Bionics (NASDAQ:EKSO) had its price objective boosted by investment analysts at HC Wainwright from $9.25 to $10.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Separately, StockNews.com raised shares of Ekso Bionics from a “sell” rating to a “hold” rating in a research report on Thursday, April 4th.

Ekso Bionics Stock Up 2.8 %

Shares of EKSO stock opened at $1.28 on Tuesday. The company has a current ratio of 2.49, a quick ratio of 1.87 and a debt-to-equity ratio of 0.38. Ekso Bionics has a 1 year low of $0.62 and a 1 year high of $3.13. The firm’s fifty day moving average price is $1.47 and its two-hundred day moving average price is $1.63. The firm has a market capitalization of $23.08 million, a P/E ratio of -1.31 and a beta of 1.61.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, April 29th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.04). Ekso Bionics had a negative net margin of 79.48% and a negative return on equity of 93.53%. The business had revenue of $3.76 million during the quarter, compared to analyst estimates of $4.99 million. During the same quarter in the previous year, the firm posted ($0.33) earnings per share. On average, equities analysts predict that Ekso Bionics will post -0.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Strategic Wealth Investment Group LLC grew its position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 25.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,665 shares of the company’s stock after acquiring an additional 8,752 shares during the period. Strategic Wealth Investment Group LLC owned about 0.30% of Ekso Bionics worth $31,000 at the end of the most recent quarter. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.